Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension

• Главные авторы: Wenxing Dong (Автор), Zhe Zhang (Автор), Mingming Chu (Автор), Peng Gu (Автор), Min Hu (Автор), Lulu Liu (Автор), Jingbin Huang (Автор), Rong Zhang (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Objective: Adding selexipag to the combined treatment of endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitor (PDE5i) reduces the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH) but at a considerably higher cost. This study evaluated the co...